| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA142928-04
|
|
p21-Activated Kinases as New Therapeutic Targets in Neurofibromatosis Type 1
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$379,935
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5R01NS034783-17
|
|
Function of Merlin, a Drosophila NF2 Gene Homologue
|
FEHON, RICHARD
|
UNIVERSITY OF CHICAGO
|
IL
|
$318,272
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5R01NS073762-03
|
|
The role of mTORC1 in the development and therapeutic targeting of NF1-associated
|
ZHU, YUAN
|
UNIVERSITY OF MICHIGAN
|
MI
|
$328,251
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5R01NS065547-04
|
|
NEUROFIBROMIN REGULATION OF NEURAL STEM CELL FUNCTION IN VITRO AND IN VIVO
|
GUTMANN, DAVID
|
WASHINGTON UNIVERSITY
|
MO
|
$314,445
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5F31NS079047-02
|
|
Merlin regulation of spinal cord NSC function
|
GARCIA, CYNTHIA
|
WASHINGTON UNIVERSITY
|
MO
|
$28,480
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA131313-05
|
|
Genetic Mouse Models of Glioma
|
PARADA, LUIS
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$365,222
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R37CA072614-17
|
|
Translational Investigation of KRas & NF1 in Myeloid Leukemia
|
SHANNON, KEVIN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$286,486
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA152975-04
|
|
Mechanism of Merlin-mediated contact inhibition and tumor suppression.
|
GIANCOTTI, FILIPPO
|
SLOAN-KETTERING INST CAN RES
|
NY
|
$452,070
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA148805-03
|
|
The Role of p21-Activated Kinases in Malignant Mesothelioma
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$348,165
|
|
Neurofibromatosis
|
2013
|
NCI
|
7R01CA153354-02
|
|
Study of Anti-Survival signals in NF1
|
CHEN, CHANGYAN
|
NORTHEASTERN UNIVERSITY
|
MA
|
$303,303
|
|
Neurofibromatosis
|
2013
|
NIMH
|
5R01MH084315-13
|
|
Mechanisms for Neurological Dysfunction in NF1 and Noonan Syndrome
|
SILVA, ALCINO
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$453,024
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA136573-05
|
|
STROMAL CONTRIBUTIONS TO NF1 GLIOMA FORMATION AND GROWTH
|
RUBIN, JOSHUA
|
WASHINGTON UNIVERSITY
|
MO
|
$287,582
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA113733-09
|
|
Molecular Function of the Nf2 Tumor Suppressor, Merlin
|
MCCLATCHEY, ANDREA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$311,292
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA166593-02
|
|
The Roles of Tumor Microenvironment in Neurofibroma Development and Therapeutics
|
LE, LU
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$310,130
|
|
Neurofibromatosis
|
2013
|
NINDS
|
1R21NS082482-01
|
|
Preclinical Treatment for NF2-Associated Tumors
|
RAMESH, VIJAYA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$217,500
|
|
Neurofibromatosis
|
2013
|
NCI
|
1R21CA175961-01
|
|
Evaluation of NF1 as a Major Breast Cancer Driver
|
SCHIMENTI, JOHN
|
CORNELL UNIVERSITY
|
NY
|
$168,200
|
|
Neurofibromatosis
|
2013
|
NIDCD
|
5R01DC010189-05
|
|
Identification of Novel Drug Targets For Use in Preventing Deafness Caused by NF2
|
FERNANDEZ-VALLE, CRISTINA
|
UNIVERSITY OF CENTRAL FLORIDA
|
FL
|
$273,738
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5R21NS077045-02
|
|
Effect of NF1 mutation on choroid plexus function
|
TEMPLE, SALLY
|
REGENERATIVE RESEARCH FOUNDATION
|
NY
|
$260,550
|
|
Neurofibromatosis
|
2013
|
NIDCD
|
1R01DC012593-01A1
|
|
Safe, Rapid Access to the Internal Auditory Canal for Acoustic Neuroma
|
WEBSTER, ROBERT
|
VANDERBILT UNIVERSITY MED CTR
|
TN
|
$361,410
|
|
Neurofibromatosis
|
2013
|
NINDS
|
1R01NS077952-01A1
|
|
Mechanisms of cell contact inhibition and their dysregulation in cancer.
|
KISSIL, JOSEPH
|
SCRIPPS FLORIDA
|
FL
|
$413,438
|
|
Neurofibromatosis
|
2013
|
NIDCD
|
5K08DC009644-05
|
|
Preclinical testing of a novel PDK1 inhibitor for treating vestibular schwannoma
|
JACOB, ABRAHAM
|
UNIVERSITY OF ARIZONA
|
AZ
|
$232,232
|
|
Neurofibromatosis
|
2013
|
NIDCD
|
5R01DC009801-05
|
|
Contribution of c-Jun N-terminal kinase activity to vestibular schwannoma growth
|
HANSEN, MARLAN
|
UNIVERSITY OF IOWA
|
IA
|
$341,402
|
|
Neurofibromatosis
|
2013
|
NIAMS
|
5R01AR055966-05
|
|
Bone Pseudoarthrosis Dissected through the Generation of New Mouse Models
|
ELEFTERIOU, FLORENT
|
VANDERBILT UNIVERSITY MED CTR
|
TN
|
$311,832
|
|
Neurofibromatosis
|
2013
|
NIDCD
|
5U24DC011943-03
|
|
Optopathology by Light Microscopy and Molecular Techniques
|
MCKENNA, MICHAEL
|
MASSACHUSETTS EYE AND EAR INFIRMARY
|
MA
|
$522,025
|
|
Neurofibromatosis
|
2013
|
NINDS
|
1F32NS083249-01
|
|
Characterizing the role of specific Ras proteins in neurofibroma and MPNST format
|
TANDON, PREETI
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$49,214
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5R01NS028840-23
|
|
Mitogenic Activities in Neurofibromatosis
|
RATNER, NANCY
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$341,429
|
|
Neurofibromatosis
|
2013
|
NCI
|
1F31CA177182-01
|
|
P21-activated kinase 1 and 2 as therapeutic targets of the NF1 microenvironment
|
KOSOFF, RACHELLE
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$28,764
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5P50NS052606-09
|
7195
|
NF Center: From animal models to therapeutics
|
PARADA, LUIS
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$451,027
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5P50NS052606-09
|
7196
|
Role of hematopoietic microenvironment in plexiform neurofibroma progression
|
CLAPP, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$358,270
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5P50NS052606-09
|
7197
|
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
|
INGRAM, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$356,843
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA111754-09
|
|
Elucidating the Function of the NF1 Tumor Suppressor and its Effector Pathways in
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$267,627
|
|
Neurofibromatosis
|
2013
|
NCI
|
5P50CA086306-14
|
5376
|
Molecular Imaging directed Diagnosis and Interrogation of Human Soft Tissue....
|
WU, HONG
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$204,029
|
|
Neurofibromatosis
|
2013
|
NCI
|
5K08CA160443-02
|
|
Axl receptor signaling in MPNST; potential node for therapy
|
TORRES, KEILA
|
UT MD ANDERSON CANCER CTR
|
TX
|
$170,618
|
|
Neurofibromatosis
|
2013
|
NCI
|
5R01CA164295-02
|
|
Exploration of Activity of RAD001 in vivo in Vestibular Schwannomas and Meningiom
|
KARAJANNIS, MATTHIAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$269,641
|
|
Neurofibromatosis
|
2013
|
NINDS
|
5R01NS081146-02
|
|
Mechanisms of Caspase-1 Mediated Schwannoma Regression
|
BRENNER, GARY
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$351,058
|
|
Neurofibromatosis
|
2013
|
NCI
|
5U54CA168512-02
|
7063
|
Identification of therapeutic windows for NF1-related malignant peripheral nerve
|
ZHU, YUAN
|
UNIVERSITY OF MICHIGAN
|
MI
|
$193,266
|
|
Neurofibromatosis
|
2013
|
NINDS
|
1F31NS081825-01A1
|
|
Evaluating the role of NRG-1 receptors in MPNST tumorigenesis
|
BROSIUS, STEPHANIE
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$32,879
|
|
Neurofibromatosis
|
2013
|
NIDCD
|
1R13NS084619-01
|
|
2013 Neurofibromatosis (NF) Conference
|
PLOTKIN, SCOTT
|
CHILDREN'S TUMOR FOUNDATION
|
NY
|
$3,000
|
|
Neurofibromatosis
|
2013
|
NINDS
|
1R13NS084619-01
|
|
2013 Neurofibromatosis (NF) Conference
|
PLOTKIN, SCOTT
|
CHILDREN'S TUMOR FOUNDATION
|
NY
|
$10,000
|
|
Neurofibromatosis
|
2013
|
NEI
|
1ZIAEY000388-12
|
|
Neuro-ophthalmic Mechanisms Of Disease
|
FITZGIBBON, EDMOND
|
NIH
|
|
$212,753
|
|
Neurofibromatosis
|
2013
|
NINDS
|
1ZIANS003053-06
|
|
Neuro-oncology of Familial Neoplasia Syndromes
|
YOULE, RICHARD
|
NIH
|
|
$1,036,604
|
|
Neurofibromatosis
|
2013
|
NINDS
|
1ZIANS003132-02
|
|
Neurooncology of Benign Central and Peripheral Nervous System Tumors
|
HEISS, JOHN
|
NIH
|
|
$1,036,604
|
|
Neurofibromatosis
|
2013
|
NCI
|
1ZIABC010539-11
|
|
Identification of Modifier Gene of Tumors Associated with NF1 and Astrocytoma
|
REILLY, KARLYNE
|
NIH
|
|
$716,470
|
|
Neurofibromatosis
|
2013
|
NCI
|
1ZIABC010540-11
|
|
Molecular Mechanisms of Proliferation and Infiltration of Astrocytoma
|
REILLY, KARLYNE
|
NIH
|
|
$204,706
|
|
Neurofibromatosis
|
2013
|
NCI
|
1ZIABC010541-11
|
|
Development of Mouse Astrocytoma Model for Preclinical Testing
|
REILLY, KARLYNE
|
NIH
|
|
$102,353
|
|
Neurofibromatosis
|
2013
|
NCI
|
1ZIABC010801-07
|
|
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes
|
WIDEMANN, BRIGITTE
|
NIH
|
|
$1,011,508
|
|
Neurofibromatosis
|
2013
|
NCI
|
1ZIABC011470-02
|
|
Development of Natural Product Leads as Anticancer Therapeutics
|
BEUTLER, JOHN
|
NIH
|
|
$313,765
|
|
Neurofibromatosis
|
2013
|
NCI
|
1ZIASC010354-14
|
|
Clinical Development of Novel Drugs for Children with Refractory Cancers
|
WIDEMANN, BRIGITTE
|
NIH
|
|
$674,339
|
|
Neurofibromatosis
|
2013
|
NCI
|
1ZIDBC011517-01
|
|
Pediatric Oncology Branch Behvioral Science Core
|
MERCHANT, MELINDA
|
NIH
|
|
$1,051,746
|
